Management Team

Peter Greenleaf

Chief Executive Officer

Mr. Greenleaf has served on our Board since May 2017. Until February 2018, Mr. Greenleaf served as Chief Executive Officer and was a member of the board of directors of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), positions he held since March 2014. Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to U.K. pharmaceutical giant Mallincrodt PLC. From June 2013 to March 2014, Mr. Greenleaf served as Chief Executive Officer and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of MedImmune, Mr. Greenleaf was Senior Vice President, Commercial Operations of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006, and at Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. He is also a member of the board of directors of the Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies and Health Sections. Mr. Greenleaf earned a M.B.A degree from St. Joseph's University and a B.S. degree from Western Connecticut State University. Our Board believes that Mr. Greenleaf's experience in the biopharmaceutical industry makes him a valuable member of our Board.

Joe Miller, CPA

Chief Financial Officer

Mr. Miller brings over 20 years of experience and a wealth of financial knowledge as a senior executive with extensive hands-on experience in managing financial operations and supporting enterprise growth across the health sciences, bio-tech and pharmaceutical sectors. In his previous role at Sucampo Pharmaceuticals, he was responsible for building out of the finance organization to effectively support the company's rapid growth, ultimately resulting in the $1.2B merger with Mallinckrodt in early 2018. Prior to Sucampo, he served in various progressive finance and management roles at Qiagen, Eppendorf and KPMG LLP. Mr. Miller's strengths include leading and building out company finance infrastructure and creating scalable, world-class organizations, making him an excellent fit into the strategic imperatives of growth and innovation at the new Cerecor. Mr. Miller holds a B.S. degree in accounting from Villanova University and is a Certified Public Accountant.

Matthew V. Phillips

Chief Commercial Officer

Matthew V. Phillips is the Chief Commercial Officer of of Cerecor, Inc. Mr. Phillips is responsible for strategic development and tactical execution of the Company's franchise of prescription medications and dietary supplements. Previously, Mr. Phillips served in various roles of increasing responsibility with Zylera Pharma Corp, where he most recently served as President.  Prior, Mr. Phillips was an integral member of the management teams at Victory Pharma, Dura Pharmaceuticals, Inc. and Eisai Co, Ltd. Mr. Phillips earned his bachelor's degree in Business from Central Michigan University, completed the University of Michigan - Executive Education Leadership Development Program and currently maintains an Appointed position on the North Carolina Board of Science, Technology and Innovation.

Perry Calias, Ph.D.

Chief Scientific Officer

Mr. Calias brings over 25 years of biopharmaceutical experience in clinical development across the drug and device sectors of healthcare. His strengths include pre-clinical, clinical development and global regulatory submissions. Dr. Calias has extensive experience in CNS and Neurology as well as Rare Diseases. He has a strong track record in compound development and pipeline progression, as well as building research and development organizations. His previous experience includes serving as Vice President of Global CMC and Product Development at Sucampo. He has held a variety of research and development positions both in clinical and non-clinical roles of expanded leadership at Shire HGT and Genzyme. Dr. Calias' strong background in early stage asset development, as well as his clinical trial experience, add to the Cerecor clinical organization as we enter into our Phase 1 trials of two of our Neurology assets. Dr. Calias obtained his Ph.D. in Organic Chemistry from Tufts University and his B.S. in biology from Suffolk University.

Heather Fraser, Ph.D.

Heather Fraser, Ph.D.

Vice President, Clinical Operations & Project Management

Dr. Fraser has served as Vice President, Clinical Operations and Project Management since October 2012, following her addition to the Company as Senior Director of Project Management earlier that year. Prior to joining Cerecor, Dr. Fraser served as the Senior Director of Preclinical and Clinical Sciences at Anthera Pharmaceuticals Inc.. Previously, Dr. Fraser served in a variety of roles at CV Therapeutics, Inc., which was acquired by Gilead Sciences, Inc. in 2009. Dr. Fraser earned a Ph.D. in Pharmacology from the University of Alberta and completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine. Dr. Fraser also earned a B.S. in Zoology from the University of British Columbia and a M.S. in Pharmaceutical Sciences from the University of Montana.

Robert E. Swedberg, CPA

Robert E. Swedberg, CPA

Vice President, Finance and Corporate Controller

Robert E. Swedberg, CPA joined Cerecor Inc. as Director of Financial Reporting in 2013, playing a key role in the Company's initial public offering (IPO), and currently serves as Vice President, Finance and Corporate Controller. Mr. Swedberg is an experienced executive with over 30 years in industries including biotechnology, pharmaceuticals, telecommunications, energy and real estate. Prior to Cerecor, Mr. Swedberg was the Chief Financial Officer of ComRent International, a heavy equipment rental company. He previously assisted in the IPO of Sucampo Pharmaceuticals as Controller and held roles at Optelecom, The Rouse Company, Ryland Homes and Main Hurdman. Mr. Swedberg has also enjoyed serving in various consulting capacities utilizing his expertise. His years of experience include controllership, SEC reporting, technical accounting, financial planning and analysis, budgeting, internal controls and SOX compliance. Mr. Swedberg earned a B.A. in Accounting from The University of Baltimore and is a member of the AICPA.

James A. Harrell, Jr.

James A. Harrell, Jr.

Executive Vice President, Marketing and External Communications

Mr. Harrell has a broad breadth of biopharmaceutical industry experience.  Since May 2013 he has been an owner and principal with the NSCI Group, Inc., a privately held medical communications and education company where he focused on new business development and brand strategy.  Prior to moving into the private sector, Mr. Harrell was Vice President and General Manager of Specialty Pharmaceuticals for Covidien running 350-person commercial operations group in the area of Pain Management from 2011 to 2013. From 2007 to late 2010 he was the Vice President of Marketing with MedImmune, Inc., responsible for their Global Pediatric Infectious Disease franchise.  From 1999 until February 2007, Mr. Harrell held various commercial positions with Centocor, Inc. with increasing levels of responsibility and management focused on the marketing of Immunotherapy and Cardiovascular products. He began his career in field sales and hospital sales at Rhone-Poulenc Rorer in 1991.  Throughout his career he has helped to commercialize and market 3 blockbuster brands. He holds a BS degree in Business Administration, with a double major in Marketing and Economics, from Samford University.